Case Report: Local injection of an IL-17 inhibitor successfully treats Acrodermatitis continua of Hallopeau and avoids immune shift - Scorecard - MDSpire
Advertisement
Case Report: Local injection of an IL-17 inhibitor successfully treats Acrodermatitis continua of Hallopeau and avoids immune shift
Clinical Scorecard: Successful Local Administration of an IL-17 Inhibitor in the Treatment of Acrodermatitis Continua of Hallopeau, Preventing Immune Shift
At a Glance
Category
Detail
Condition
Acrodermatitis Continua of Hallopeau (ACH)
Key Mechanisms
Involves IL-17 pathway; local administration prevents immune drift.
Target Population
Patients with refractory ACH, particularly in pediatric populations.
Care Setting
Clinical setting with access to biologic therapies.
Key Highlights
First report of local IL-17 inhibitor injections for ACH.
Significant improvement in PPPASI, DLQI, and NAPSI scores.
No recurrence of immune drift or systemic adverse reactions.
Treatment involved diluted Xeligekimab injections every two weeks.
Patient experienced marked clinical efficacy after local treatment.
Guideline-Based Recommendations
Diagnosis
Diagnosis based on clinical presentation of pustules, nail dystrophy, and scaling.
Management
Consider local administration of IL-17 inhibitors for refractory cases.
Monitoring & Follow-up
Monitor for signs of immune drift and treatment efficacy through PPPASI, DLQI, and NAPSI.
Risks
Potential for eczematous eruptions with systemic IL-17 inhibitors.
Patient & Prescribing Data
13-year-old female with refractory ACH.
Local injections of diluted Xeligekimab were effective in controlling lesions.
Clinical Best Practices
Use diluted local injections to minimize systemic effects.
Monitor patient quality of life and disease severity indices regularly.
